Effect of t(11;14) on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect® MM Registry

https://doi.org/10.1016/j.clml.2019.09.118Get rights and content

Section snippets

Background

t(11;14) is found in 16%–24% of multiple myeloma [MM] patients and is generally classified as standard risk (Sonneveld et al. Blood. 2016). Its effect on MM prognosis is not fully understood. Consensus is lacking on the effects of induction treatment on outcomes with t(11;14). The Connect® MM Registry (NCT01081028) is a large, US, multicenter, prospective observational cohort study of patients with newly diagnosed MM designed to examine real-world diagnostic patterns, treatment patterns,

Methods

Analysis included data from patients from 250 community, academic, and government sites in cohort 1 (9/2009–12/2011) and cohort 2 (12/2012–4/2016), who completed first-line induction treatment (IMiD agent [lenalidomide or pomalidomide] + proteasome inhibitor [PI], PI only, or IMiD agent only) and were tested for t(11;14) by fluorescence in situ hybridization or cytogenetics. Primary end points (progression-free survival and overall survival) were measured from start of first-line treatment to

Results

As of 1/2018, 3011 patients were enrolled; 2938 were treated. Of 1574 enrolled patients tested for t(11;14), 378 were t(11;14)+ and 1196 were t(11;14)−. More patients in cohort 2 than cohort 1 were t(11;14)+ (60% vs 40%). Baseline characteristics were similar between groups. t(11;14) status did not significantly affect progression-free survival (for all treated patients [34.8 vs 35.7 mo] and each treatment group [IMiD agent + PI, 42.6 vs 45.2 mo; PI only, 32.9 vs 29.5; IMiD agent only, 30.3 vs

Conclusion

Results of this analysis of real-world data from the Connect MM Registry, a large, US-based MM registry, suggest that t(11;14) does not affect progression-free survival and overall survival outcomes in newly diagnosed MM patients with currently utilized treatment regimens.

Keywords

induction

survival

t(11;14)

Tracks

Multiple Myeloma Genomics

References (0)

Cited by (0)

View full text